Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Fiche du document

Auteurs
Date

18 juin 2015

Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1056/NEJMoa1410489

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/26039521

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1533-4406

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D896913B6E933

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Acute Coronary Syndrome/drug therapy; Aged; Anticholesteremic Agents/adverse effects; Anticholesteremic Agents/therapeutic use; Azetidines/adverse effects; Azetidines/therapeutic use; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/mortality; Cardiovascular Diseases/prevention & control; Cholesterol, LDL/blood; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Kaplan-Meier Estimate; Male; Middle Aged; Simvastatin/therapeutic use; Triglycerides/blood

Sujets proches En

Cholesterin

Citer ce document

C.P. Cannon et al., « Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. », Serveur académique Lausannois, ID : 10.1056/NEJMoa1410489

Métriques

Partage / Export

Résumé 0

Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke. The median follow-up was 6 years. The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en